Clinical Trial Search

Primary: Evaluation of Acceptability of Intervention as Measured by Acceptability Questionnaire — 4.47 score on a scale

Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…

Primary: SARS-CoV-2 Infection — 4; 2 Participants

Primary: PTSD Symptom Severity — 16.36; 17.10; 15.56; 15.78 score on a scale — p=.77

Primary: The Percent of Participants With Tracheal Intubation or Death Prior to Tracheal Intubation — 26.2; 22.2 percentage of participants

Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants

Primary: Difference in Days Alive and Out of Hospital — 29.5; 29.4 days

Primary: Number of Participants With Problems in Their Health Care Due to COVID-19 Related Isolation — 155 Participants

Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants

Primary: Number of Participants Intubated During Hospitalization — 8; 25 Participants — p=0.297

Primary: The Incidence of COVID-2019 Cases. — 259.95 COVID-2019 cases per 1000 person

Primary: Measure of Daily Stool Frequency for Patients With COVID Treated With Bismuth — 3 bowel movements

Primary: Help Seeking Intention — 7.4; 7.9; 7.3; 8.2 units on a scale — p=0.031

Primary: Motor Balance as Measured by Timed Up and Go (TUG) — 20.57 seconds

Primary: Number of Participants With National Early Warning Score (NEWS) Change From 3 to 0 — 44; 29 Participants

Primary: Brief Psychiatric Rating Scale (BPRS) — 29.30; 32.80; 30.25 score on a scale

Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…

Primary: Time in Range — 21.6 percentage of time

Primary: Body Temperature — 98.1 degrees Fahrenheit

Primary: Patient Choosing Telehealth as an Option for Future Care — 523; 43; 36 Participants

Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants

Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant

Primary: Deterioration Resulting in Healthcare Review — 10 alerts generated

Primary: Negative Polymerase Chain Reaction (PCR) — 2; 7 Participants

Primary: Duration of Viral Shedding — 9.532447; 10.39556 Days

Primary: Frequency of Any Medically-attended Adverse Events (MAAEs) — 7; 6; 5; 7 Participants

Primary: Total Number of Serious Adverse Events (SAE) Through Study Day 14 — 0; 0 Serious Adverse Events

Primary: Percent Change in D-dimer — -5.6; -2.4 percent daily change — p=0.24

Primary: Testing Barriers and Hesitancy — 0.29; 0.24 score on a scale — p=0.09

Primary: Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline — 56; 5; 27 Participants — p=.28